Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.38 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.38 |
| ▸ | GRIK4 | Q16099 | 1/20 | 0.38 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | DDR1 | Q08345 | 8/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.37 |
| ▸ | PPARG | P37231 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2387606 | 0.84 | CA12 (0.36) | CA12CA9DDR1 | |
| SCHEMBL4627649 | 0.84 | CA12 (0.38) | CA12CA9DDR1 | |
| SCHEMBL2391466 | 0.84 | DDR1 (0.38) | CA12CA9DDR1 | |
| SCHEMBL2390017 | 0.84 | DDR1 (0.38) | CA12CA9DDR1 | |
| SCHEMBL2387541 | 0.83 | GRIK1 (0.40) | GRIK1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL1661288 | 0.82 | DDR1 (0.37) | CA12CA9DDR1 | |
| SCHEMBL2388789 | 0.81 | CA12 (0.40) | GRIK1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL2389873 | 0.80 | DDR1 (0.41) | DDR1 | |
| SCHEMBL4627730 | 0.80 | DDR1 (0.37) | CA12CA9DDR1 | |
| SCHEMBL2391002 | 0.79 | CA12 (0.38) | CA12CA9DDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130296332-A1 | 1H-QUINAZOLINE-2,4-DIONES | NOVARTIS AG (CH) | 2013-11-07 | — | — | US | disclosed |
| US-20130296332-A1 | 1H-QUINAZOLINE-2,4-DIONES | NOVARTIS AG (CH) | 2013-11-07 | — | — | US | disclosed |
| US-8513268-B2 | 1H-quinazoline-2,4-diones processes for their production, pharmaceutical compositions, and treatment for epilepsy | NOVARTIS AG (CH) | 2013-08-20 | — | — | US | disclosed |
| US-8513268-B2 | 1H-quinazoline-2,4-diones processes for their production, pharmaceutical compositions, and treatment for epilepsy | NOVARTIS AG (CH) | 2013-08-20 | — | — | US | disclosed |
| EP-2476671-A1 | 1H-Quinazoline-2,4-diones | Novartis AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| EP-2476671-A1 | 1H-Quinazoline-2,4-diones | Novartis AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| EP-2468732-A1 | 1H-Quinazoline-2,4-diones | Novartis AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| EP-2468732-A1 | 1H-Quinazoline-2,4-diones | Novartis AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| EP-2463278-A1 | 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS | Novartis AG (CH) | 2012-06-13 | — | — | EP | disclosed |
| EP-2463278-A1 | 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS | Novartis AG (CH) | 2012-06-13 | — | — | EP | disclosed |
| US-20100144747-A1 | 1H-QUINAZ0LINE-2,4-DIONES | NOVARTIS AG | 2010-06-10 | — | — | US | disclosed |
| US-20100144747-A1 | 1H-QUINAZ0LINE-2,4-DIONES | NOVARTIS AG | 2010-06-10 | — | — | US | disclosed |
| US-7655666-B2 | Substituted 1H-quinazoline-2,4-diones useful as AMPA receptor ligands | NOVARTIS AG (CH) | 2010-02-02 | — | — | US | disclosed |
| US-7655666-B2 | Substituted 1H-quinazoline-2,4-diones useful as AMPA receptor ligands | NOVARTIS AG (CH) | 2010-02-02 | — | — | US | disclosed |
| US-7655666-B2 | Substituted 1H-quinazoline-2,4-diones useful as AMPA receptor ligands | NOVARTIS AG (CH) | 2010-02-02 | — | — | US | disclosed |
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | NOVARTIS AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | NOVARTIS AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | NOVARTIS AG (CH) | 2008-06-26 | — | — | US | disclosed |
| EP-1871749-A1 | 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS | Novartis AG (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006108591-A1 | 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144747-A1 | 1H-QUINAZ0LINE-2,4-DIONES | CYP3A7, CYP1A2, UGT1A7 | GRIK1 1797/4885GRIA1 739/4885GRIA2 792/4885 |
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | GRIN2A, GRIN1, GRIN2D | GRIK1 9/4885GRIA1 26/4885GRIA2 33/4885 |
| US-20130296332-A1 | 1H-QUINAZOLINE-2,4-DIONES | CYP1A2, QDPR, CYP3A7 | GRIK1 1056/4885GRIA1 651/4885GRIA2 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.